203
Views
9
CrossRef citations to date
0
Altmetric
Medical Dermatology

Toll-like receptor 9 in systemic lupus erythematosus, impact on glucocorticoid treatment

, , &
Pages 411-417 | Received 11 Jan 2012, Accepted 30 Apr 2012, Published online: 05 Aug 2012

References

  • Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003;56:481–490.
  • Christensen SR, Shlomchik MJ. Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin Immunol. 2007;19:11–23.
  • Horton CG, Pan ZJ, Farris AD. Targeting Toll-Like receptors for treatment of SLE. Mediators Inflamm. 2010;19:1–9.
  • Heit A, Huster KM, Schmitz F, Schiemann M, Busch DH, Wagner H. CpG-DNA aided cross-priming by cross presenting B cells. J Immunol. 2004;172:1501–1507.
  • Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 2004;416:603–607.
  • Papadimitraki ED, Choulaki C, Koutala E, Bertsias G, Tsatsanis C, Gergianaki I, Raptopoulou A, Kritikos HD, et al. Expansion of toll like receptor 9 -expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum. 2006;54:3601–3611.
  • Chatham WW, Kimberly RP. Treatment of lupus with corticosteroids. Lupus. 2001;10:140–147.
  • Chaussabel D, Quinne C, Shen J, Patel P, Glaser C, Baldwin N, Stichweh D, Blankenship D, et al. A modular analysis framework for blood genomics studies:application to systemic lupus erythematosus. Immunity. 2008;29:150–164.
  • Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, Chang B, Duramad O, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med. 2005;202:1131–1139.
  • Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725–1734.
  • Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol. 2005;19:685–708.
  • Virella G. Nephelometric techniques in immunodiagnosis. Clin Immunol Newsl. 1980;1:1–16.
  • Viberti GC, Pickup JC, Jarrett RJ, Keen H. Effect of control of blood glucose on urinary excretion of albumin and beta 2 microglobulin in insulin- dependent diabetes. N Engl J Med. 1979;300:638–641.
  • Bartels H, BohmerM, Micro-detremination of creatinine. Clin Chim Acta. 1971;32:81–85.
  • Komatsuda A, Wakui H, Iwamoto K, Ozawa M, Togashi M, Masai R, Maki N, Hatakeyama T, et al. Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol. 2008;152:482–487.
  • Nakano S, Morimoto J, Suzuki K, Nozawa:. H, AmanoYTokanoY. Role of pathogenic auto- antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology. 2008;47:145–149.
  • Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med. 2006;203:553–561.
  • Sekigawa I, Okada M, Ogasawara H, Kaneko H, Hishikawa T, Hashimoto H. DNA methylation in systemic lupus erythematosus. Lupus. 2003;12:79–85.
  • Dalpke AH, Lehner MD, Hartung T, Heeg K. Differential effects of CpG-DNA in Toll-like receptor -2/-4/-9/tolerance and cross-tolerance. Immunology. 2005;116:203–212.
  • Visentini M, Conti V, Cagliuso M. Regression of Systemic Lupus Erythematosus After Development of an Acquired Toll-like Receptor Signaling Defect and Antibody deficiency. Arthritis Rheum. 2009;60:2767–2771.
  • Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus Autoantibody -DNA complexes activate DCs through cooperation of CD32 and LR9. J Clin Invest. 2005;115:407–417.
  • Barrat FJ, Meeker T, Gregorio J. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med. 2005;202:1131–1139.
  • Migita K, Miyashita T, Maeda Y, Nakamura M, Yatsuhashi H, Kimura H, Ishibashi H, Eguchi K. Toll-like receptor expression in lupus peripheral blood mononuclear cells. J Rheumatol. 2007;34:493–500.
  • Lit LC, Wong CK, Tam LS, Li EK, Lam CW. Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis. 2006;65:209–215.
  • Lartigue A, Courville P, Auquit I, François A, Arnoult C, Tron F, Gilbert D, Musette P. Role of TLR9 in antinucleosome and anti- DNA antibody production in lpr mutation induced murine lupus. J Immunol. 2006.
  • Wu X, Peng SL. Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheumatol. 2006;54:336–342.
  • Boor PP, Metselaar HJ, Mancham S, Tilanus HW, Kusters JG, Kwekkeboom J. Prednisolone suppresses the function and promotes apoptosis of plasmacytoid dendritic cells. Am J Transplant. 2006;6:2332–2341.
  • Guiducci C. PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. J Exp Med. 2008;205:315–322.
  • Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, Meeker T, Chan JH, Wright T, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature. 2010;465(7300):937–41.
  • Pawar RD, Ramanjaneyulu A, Kulkarni OP, Lech M, Segerer S, Anders HJ. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol. 2007;18:1721–1731.
  • Valins W, Amini BS, Brian CB. The expression of toll-like receptors in dermatological diseases and the therapeutic effect of current and newer topical toll-like receptor modulators. J Clin Aesthet Dermatol. 2010;3:20–29.
  • Lenert P. Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA and/or RNA like analogues for treating lupus. Clin Exp Immunol. 2010;161:208–222.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.